These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18615900)

  • 1. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene.
    Kanková K; Kalousová M; Hertlová M; Krusová D; Olsovský J; Zima T
    Arch Physiol Biochem; 2008 Apr; 114(2):111-9. PubMed ID: 18615900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
    Abdel-Azeez HA; El-Okely AM
    Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
    Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
    Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
    Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
    Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
    Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
    Lu L; Peng WH; Wang W; Wang LJ; Chen QJ; Shen WF
    J Zhejiang Univ Sci B; 2011 Aug; 12(8):652-9. PubMed ID: 21796806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.
    Semba RD; Ferrucci L; Fink JC; Sun K; Beck J; Dalal M; Guralnik JM; Fried LP
    Am J Kidney Dis; 2009 Jan; 53(1):51-8. PubMed ID: 18789567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.
    Loomis SJ; Chen Y; Sacks DB; Christenson ES; Christenson RH; Rebholz CM; Selvin E
    Clin Chem; 2017 May; 63(5):980-989. PubMed ID: 28280052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes.
    Salonen KM; Ryhänen SJ; Forbes JM; Härkönen T; Ilonen J; Laine AP; Groop PH; Knip M;
    Diabetes Care; 2014 Jul; 37(7):1975-81. PubMed ID: 24742661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels.
    Gaens KH; Ferreira I; van der Kallen CJ; van Greevenbroek MM; Blaak EE; Feskens EJ; Dekker JM; Nijpels G; Heine RJ; 't Hart LM; de Groot PG; Stehouwer CD; Schalkwijk CG
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5174-80. PubMed ID: 19890027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
    Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
    Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of tubular epithelial cells in diabetic nephropathy.
    Morcos M; Sayed AA; Bierhaus A; Yard B; Waldherr R; Merz W; Kloeting I; Schleicher E; Mentz S; Abd el Baki RF; Tritschler H; Kasper M; Schwenger V; Hamann A; Dugi KA; Schmidt AM; Stern D; Ziegler R; Haering HU; Andrassy M; van der Woude F; Nawroth PP
    Diabetes; 2002 Dec; 51(12):3532-44. PubMed ID: 12453911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between the G82S Polymorphism of the Receptor Gene for Advanced Glycation End-products and Soluble Serum Levels RAGE with Diabetic Nephropathy in the White (Asian) Race.
    Rezaei Arnesa A; Hajian S; Salemi Bazargani S; Salahshourifar I; Moghbelinejad S; Abdolvahabi Z; Yaghoobzadeh H; Fathi M; Piri H
    Iran J Kidney Dis; 2024 May; 18(3):179-186. PubMed ID: 38904338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.